LSD-based DT120 posts Phase 3 win in anxiety, signaling a new treatment era
Definium’s DT120, an LSD-based psychedelic therapy, delivered a pivotal Phase 3 win for generalized anxiety disorder, with a single dose reducing HAM-A scores by 11.6 points at 12 weeks versus 6.2 for placebo in a 214-patient trial. This follows a successful depression study, boosting optimism for psychedelic medicines and positioning the Panorama trial (with a second dose arm) as the next readout. If confirmed and supported by FDA discussions, the approach could offer a new, mechanism-different option beyond benzodiazepines and SSRIs for anxiety.